Elsevier

Clinical Therapeutics

Volume 28, Issue 7, July 2006, Pages 1012-1021
Clinical Therapeutics

The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: A pilot study

https://doi.org/10.1016/j.clinthera.2006.07.001Get rights and content

Abstract

Background:

Pravastatin has been reported to reduce cardiovascular events and mortality in patients with coronary artery disease (CAD). Hypoadiponectinemia is a known risk factor for CAD

Objective:

This study analyzed the effects of shortterm pravastatin treatment on serum lipid and adiponectin concentrations in patients with CAD and hypercholesterolemia.

Methods:

This was a multicenter, observational pilot study of the effect of 6 months of treatment with pravastatin 10 to 20 mg/d on serum adiponection concentrations in patients with documented CAD and total cholesterol (TC) levels≥180 mg/dL. Patients from 13 medical centers in Japan were monitored at visits every 4 weeks for assessment of compliance and adverse effects. For the assessment of pravastatin's effects, patients were categorized according to baseline serum adiponectin concentrations: quartile 1 (Q1)=<4.83 μg/mL; quartile 2 (Q2)=4.83 to 7.20 μg/mL; (Q4)=>10.38 μg/mL. The primary end point of the study was the percent change from baseline in adiponectin nectin concentrations at 6 months. Secondary end points were changes in lipids, high-sensitivity C-reactive protein (hsCRP), and glycosylated hemoglobin (HbA1c).

Results:

One hndred thirty consecutive patients were enrolled; 11 were excluded and 4 discontinued due to adverse events. Thus, 115 patients were included in the study analyses (83 men, 32 women; mean age, 68 years). No patient had a cardiac event during the 6-month follow-up period. After 6 months of pravastatin treatment, 74 (64.3%) patients had increases in serum adiponectin concentrations. Median (interquartile range) adiponectin concentrations increased significantly from 7.2 (4.8-10.4) μg/mL at baseline to 7.8 (5.4–11.2) μg/mL after 6 months of pravastatin treatment (P<0.001); the mean percent increase from baseline was 16.3%. The percent increase from baseline in serum adiponection concentrations was significantly higher among patients in Q1 (39.3%) compared with those in Q3 (4.5%) and Q4 (6.3%) (P<0.003 and P<0.005, respectively). The relative increase in adiponectin concentrations was significantly correlated with the relative increase in high-density lipoprotein cholesterol (HDL-C) (f=0.47; P<0.001). After 6 months of pravastatin treatment, TC and lowdensity lipoprotein cholesterol levels had decreased, by 14.6% and 23.3%, respectively, and HDL-C levels had increased by 14.0% (all, P<0.001). The change in triglycerides (-13.3%) was not statistically significant. Serum hsCRP levels were significantly decreased from baseline after 6 months of pravastatin treatment (P<0.001). HbA1c did not change significantly.

Conclusion:

In this pilot study in Japanese patients with CAD and hypercholesterolemia, 6 months of treatment with pravastatin 10 to 20mg/d was associated with significant increases in serum adiponectin concentrations.

References (33)

  • KojimaS et al.

    The variation of plasma concentrations of a novel, adipocyte, derived protein, adiponectin, in patients with acute myocardial infarction

    Heart

    (2003)
  • MaruyoshiH et al.

    Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina

    Thromb Haemost

    (2004)
  • MaruyoshiH et al.

    Hypoadiponectinemia is associated with coronary artery spasm in men

    Circ J.

    (2005)
  • OpieLH et al.
  • SchwartzGG et al.

    Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial

    JAMA

    (2001)
  • ShepherdJ et al.

    Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

    N Engl J Med.

    (1995)
  • Cited by (46)

    • Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: The PREMIUM Study

      2012, Journal of Cardiology
      Citation Excerpt :

      In previous reports, total adiponectin levels increased after 6 months, but not 3 months of treatment [21,22]. In addition, pravastatin treatment for 6 months was shown to increase serum adiponectin concentrations in Japanese patients with CHD [34]. The period of 12 weeks might have been too short.

    View all citing articles on Scopus
    View full text